We found COVID-19 context-specific increasing dosage effect of the risk allele (rs13050728-T) on IFNAR2 expression levels in monocytes (β = 0.030, 95% CI = 0.011–0.049, P = 2.7 × 10−3 for COVID-19 and β = 4.9 × 10−4, 95% CI = −0.010 to 0.011, P = 0.93 for healthy controls), especially in cMono (β = 0.030, 95%CI = 0.012–0.049, P = 2.3 × 10−3 for COVID-19 and β = 3.7 × 10−3, 95% CI = −5.2 × 10−3 to 0.013, P = 0.42 for healthy controls; Fig. 7c, Extended Data Fig. 7b and Supplementary Tables 8 and 9). This evidence concerns the gene IFNAR2 and COVID-19.